| Vol. 13.03 – 28 January, 2022 |
| |
|
|
| DNA-dependent kinase catalytic subunit (DNA-PK) regulation of metabolism was interrogated using pharmacological and genetic perturbation using in vitro cell models, in vivo xenografts, and ex vivo in patient-derived explants. [Clinical Cancer Research] |
| |
|
|
PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Scientists identified thioesterase superfamily member 6 (THEM6) as a marker of androgen-deprivation therapy resistance in prostate cancer. THEM6 deletion reduced in vivo tumor growth and restored castration sensitivity in orthograft models of CRPC. [EMBO Molecular Medicine] |
|
|
|
| PKCβ inhibition reduced total androgen receptor (AR) gene expression, thus reducing AR-V7 protein levels and sensitizing prostate cancer cells to current anti-androgen therapies. [Oncogene] |
|
|
|
| Researchers suggested that E2F transcription factor 2-activated DLEU2 may function as a competing endogenous RNA to facilitate prostate cancer progression by targeting the miR-582-5p/SGK1 axis. [Cell Death & Disease] |
|
|
|
| Investigators characterized responses to olaparib in sensitive LNCaP and C4-2B cells and developed two olaparib resistant derivative cell line models from each. They found that olaparib induced massive DNA damage, leading to activation of the G2/M checkpoint, activation of p53, and cell cycle arrest. [Molecular Cancer therapeutics] |
|
|
|
| Scientists investigated the response of PTEN wild-type prostate cancer cell lines to the dual PI3K/mTOR inhibitor DS-7423 alone or in combination with HER2 inhibitors or mGluR1 inhibitors. [Molecular Cancer therapeutics] |
|
|
|
| Integrated copy number aberration and gene expression analysis of primary high-risk prostate cancer identified the AZIN1 gene as a novel driver of metastatic progression, by altering collagen subunit expression. [Molecular Cancer Research] |
|
|
|
| The authors investigated the therapeutic potential of liposomes containing perforin expression vector driven by the promotor of prostate-specific antigen. [Scientific Reports] |
|
|
|
| In vitro and in vivo functional characterization revealed that overexpression of NCAPD3 enhanced the growth of prostate cancer (PCa) cells, while knockdown of NCAPD3 impaired the growth of PCa cells. [Cellular Signalling] |
|
|
|
| Researchers found that the increase of transcription factor 6 α (ATF6α) expression in response to androgen deprivation generated prostate cancer cells with a CRPC-like phenotype. [Prostate] |
| |
|
|
|
| The authors provide an overview of the intrinsic functional properties of luminal progenitor cells, and address their relevance in mouse and human prostate pathophysiology. [Nature Reviews Urology] |
|
|
|
| Investigators provide a detailed overview of the current knowledge of the role of the human microbiome in prostate cancer development, progression, and treatment response. [Journal of Experimental & Clinical Cancer Research] |
|
|
|
| The use of genomic testing for prostate cancer continues to grow; however, utilization remains institutionally dependent. Scientists review current tissue-based markers and comment on current use with active surveillance and prostate MRI. [Current Oncology Reports] |
|
|
|
|
| Telix Pharmaceuticals Limited announced that the first patient has been dosed in the company’s prostate-specific membrane antigen targeting ‘ProstACT’ therapeutic program, which is exploring TLX591 in areas of unmet medical need across the full prostate cancer treatment journey. [Telix Pharmaceuticals Limited] |
|
|
|
|
| March 9 – 11, 2022 Melbourne, Victoria, Australia |
|
|
|
|
|
| Cleveland Clinic Lerner Research Institute – Cleveland, Ohio, United States |
|
|
|
| Henry M. Jackson Foundation for the Advancement of Military Medicine – Bethesda, Maryland, United States |
|
|
|
| University of Maryland, Baltimore – Baltimore, Maryland, United States |
|
|
|
| Wayne State University School of Medicine – Detroit, Michigan, United States |
|
|
|
| Icahn School of Medicine at Mount Sinai – New York, New York, United States |
|
|
|
|